HUTCHMED DRC Financials
HCM Stock | USD 18.43 1.05 6.04% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 1.91 | 2.7215 |
|
|
The financial analysis of HUTCHMED DRC is a critical element in measuring its lifeblood. Investors should not minimize HUTCHMED DRC's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
HUTCHMED | Select Account or Indicator |
Understanding current and past HUTCHMED DRC Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of HUTCHMED DRC's financial statements are interrelated, with each one affecting the others. For example, an increase in HUTCHMED DRC's assets may result in an increase in income on the income statement.
HUTCHMED DRC Stock Summary
HUTCHMED DRC competes with ANI Pharmaceuticals, Phibro Animal, Prestige Brand, Pacira BioSciences,, and Collegium Pharmaceutical. HUTCHMED Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchmed China operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 2110 people.Foreign Associate | UK |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US44842L1035 |
CUSIP | 44842L103 |
Location | Hong Kong |
Business Address | Cheung Kong Center, |
Sector | Pharmaceuticals |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.hutch-med.com |
Phone | 852 2121 8200 |
Currency | USD - US Dollar |
HUTCHMED DRC Key Financial Ratios
Return On Equity | -0.0544 | ||||
Profit Margin | (0.07) % | ||||
Operating Margin | (0.09) % | ||||
Price To Sales | 4.97 X | ||||
Revenue | 838 M |
HUTCHMED DRC Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 465.1M | 724.1M | 1.4B | 1.0B | 1.3B | 1.3B | |
Other Current Liab | 445K | 122.9M | 228.0M | 278.0M | 271.4M | 285.0M | |
Net Debt | (88.1M) | (199.9M) | (343.5M) | (290.0M) | (197.5M) | (187.6M) | |
Retained Earnings | (289.7M) | (415.6M) | (610.3M) | (971.5M) | (870.9M) | (827.3M) | |
Accounts Payable | 24.0M | 31.6M | 41.2M | 71.1M | 36.3M | 24.7M | |
Cash | 121.2M | 235.6M | 377.5M | 313.3M | 283.6M | 297.8M | |
Inventory | 16.2M | 19.8M | 35.8M | 56.7M | 50.3M | 52.8M | |
Other Current Assets | 42.2M | 75.8M | 16.9M | 25.5M | 9.8M | 9.3M | |
Total Liab | 152.2M | 205.2M | 333.1M | 392.6M | 536.4M | 563.2M | |
Total Current Assets | 317.0M | 530.7M | 1.2B | 839.9M | 1.1B | 1.2B | |
Short Term Debt | 3.2M | 2.8M | 26.9M | 3.7M | 35.1M | 18.8M | |
Intangible Assets | 275K | 227K | 163K | 3.2M | 21K | 20.0K | |
Common Stock | 66.7M | 72.8M | 86.5M | 86.5M | 87.1M | 68.2M | |
Net Receivables | 41.4M | 47.9M | 147.7M | 126.7M | 150.5M | 158.0M | |
Good Will | 3.2M | 3.1M | 3.3M | 3.4M | 3.1M | 2.6M | |
Other Liab | 8.7M | 13.3M | 14.3M | 15.4M | 17.7M | 10.1M | |
Net Tangible Assets | 284.6M | 480.6M | 983.4M | 610.4M | 701.9M | 394.5M | |
Other Assets | 24.2M | 18.2M | 27.4M | 31.1M | 1.0 | 0.95 | |
Long Term Debt | 26.7M | 26.8M | 26.9M | 18.1M | 48.2M | 25.3M |
HUTCHMED DRC Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 1.0M | 787K | 592K | 652K | 759K | 879.4K | |
Total Revenue | 204.9M | 228.0M | 356.1M | 426.4M | 838.0M | 879.9M | |
Gross Profit | 44.7M | 39.5M | 97.9M | 115.3M | 453.6M | 476.2M | |
Operating Income | (145.0M) | (188.9M) | (336.5M) | (409.8M) | 18.4M | 19.3M | |
Ebit | (145.0M) | (188.9M) | (215.1M) | (409.8M) | 17.3M | 18.2M | |
Research Development | 91.9M | 111.2M | 207.4M | 267.6M | 303.1M | 318.2M | |
Ebitda | (135.1M) | (182.9M) | (208.0M) | (401.1M) | 25.5M | 26.8M | |
Cost Of Revenue | 160.2M | 188.5M | 258.2M | 311.1M | 384.4M | 403.7M | |
Income Before Tax | (141.1M) | (189.7M) | (215.7M) | (410.4M) | 58.3M | 61.2M | |
Net Income | (144.4M) | (194.6M) | (227.7M) | (410.1M) | 100.8M | 105.8M | |
Income Tax Expense | 3.3M | 4.8M | 11.9M | (283K) | 4.5M | 3.1M | |
Minority Interest | 24.9M | 34.8M | (27.6M) | (449K) | (314K) | (298.3K) | |
Tax Provision | 3.3M | 4.8M | 11.9M | (283K) | 4.5M | 4.5M | |
Interest Income | 4.9M | 3.2M | 2.1M | 9.6M | 36.1M | 38.0M | |
Net Interest Income | 3.9M | 2.4M | 1.5M | 8.9M | 35.4M | 37.2M |
HUTCHMED DRC Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | (4.2M) | (3.6M) | (16.0M) | (21.2M) | 4.1M | 4.3M | |
Change In Cash | 35.1M | 114.5M | 141.9M | (64.3M) | (29.7M) | (28.2M) | |
Free Cash Flow | (89.5M) | (81.6M) | (221.0M) | (305.3M) | 186.6M | 196.0M | |
Depreciation | 4.9M | 6.1M | 7.2M | 8.7M | 8.2M | 4.6M | |
Other Non Cash Items | 394K | (2.1M) | (3.7M) | (6.2M) | 105.3M | 110.5M | |
Capital Expenditures | 8.6M | 19.6M | 16.8M | 36.7M | 32.6M | 34.2M | |
Net Income | (103.7M) | (115.5M) | (167.0M) | (360.4M) | 100.8M | 105.8M | |
End Period Cash Flow | 121.2M | 235.6M | 377.5M | 313.3M | 283.6M | 297.8M | |
Dividends Paid | 28.1M | 35K | 99.7M | 87.4M | 123.4M | 129.6M | |
Investments | 119.0M | (125.4M) | (275.5M) | 296.6M | (291.1M) | (276.6M) | |
Net Borrowings | (4.6M) | (116K) | (579K) | (9.2M) | (8.3M) | (7.8M) | |
Change To Netincome | 3.9M | 28.3M | (49.3M) | 24.9M | 22.4M | 23.5M |
HUTCHMED Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining HUTCHMED DRC's current stock value. Our valuation model uses many indicators to compare HUTCHMED DRC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across HUTCHMED DRC competition to find correlations between indicators driving HUTCHMED DRC's intrinsic value. More Info.HUTCHMED DRC is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, HUTCHMED DRC's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value HUTCHMED DRC by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.HUTCHMED DRC Systematic Risk
HUTCHMED DRC's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. HUTCHMED DRC volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on HUTCHMED DRC correlated with the market. If Beta is less than 0 HUTCHMED DRC generally moves in the opposite direction as compared to the market. If HUTCHMED DRC Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one HUTCHMED DRC is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of HUTCHMED DRC is generally in the same direction as the market. If Beta > 1 HUTCHMED DRC moves generally in the same direction as, but more than the movement of the benchmark.
HUTCHMED DRC Thematic Clasifications
HUTCHMED DRC is part of several thematic ideas from Drugs to Health Management. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasToday, most investors in HUTCHMED DRC Stock are looking for potential investment opportunities by analyzing not only static indicators but also various HUTCHMED DRC's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of HUTCHMED DRC growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
HUTCHMED DRC November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of HUTCHMED DRC help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of HUTCHMED DRC. We use our internally-developed statistical techniques to arrive at the intrinsic value of HUTCHMED DRC based on widely used predictive technical indicators. In general, we focus on analyzing HUTCHMED Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build HUTCHMED DRC's daily price indicators and compare them against related drivers.
Downside Deviation | 2.74 | |||
Information Ratio | (0.02) | |||
Maximum Drawdown | 12.71 | |||
Value At Risk | (5.01) | |||
Potential Upside | 5.32 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HUTCHMED DRC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in HUTCHMED Stock, please use our How to Invest in HUTCHMED DRC guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HUTCHMED DRC. If investors know HUTCHMED will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HUTCHMED DRC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.84) | Earnings Share (0.25) | Revenue Per Share 3.575 | Quarterly Revenue Growth (0.43) | Return On Assets (0.06) |
The market value of HUTCHMED DRC is measured differently than its book value, which is the value of HUTCHMED that is recorded on the company's balance sheet. Investors also form their own opinion of HUTCHMED DRC's value that differs from its market value or its book value, called intrinsic value, which is HUTCHMED DRC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HUTCHMED DRC's market value can be influenced by many factors that don't directly affect HUTCHMED DRC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HUTCHMED DRC's value and its price as these two are different measures arrived at by different means. Investors typically determine if HUTCHMED DRC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HUTCHMED DRC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.